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Bio-macromolecules (e.g. protein, peptide, antibody DNA or RNA) present in our bodies are now widely utilized 
in pharmaceuticals. Carbohydrates, on the other hand, have been receiving increasing attention as drug 
candidates, but the pharmaceutical usage of carbohydrates is limited to few glycosaminoglycans (e.g. heparin, 
hyaluronan or chondroitin sulfate), which are all endogenous polysaccharides. Glycogen is another 
polysaccharide present in our bodies as energy reserves, and its application for pharmaceuticals is not evident 
either. 
 
Glycogen is a highly branched polysaccharide of glucose with a very attractive structure and characteristics. It is 
a single molecular nano-sized spherical particle with dendritic architecture where numerous non-reducing ends 
constitute the surface of the molecule. Dendrimers and nano-sized particles have received interest as carriers 
for drug delivery system because such carriers can enhance the performance and efficacy of drug molecules. 
From this context, we consider glycogen as potentially a promising polysaccharide as drug carriers; therefore 
we are currently attempting to develop synthetic glucan dendrimers suitable for drug carriers. Such attempts 
have been scarce in the recent research of drug candidates. 
 
We have developed an enzymatic system to produce glucan dendrimer (GD) from sucrose by combined action 
of sucrose phosphorylase (EC: 2.4.1.7), glucan phosphorylase (EC: 2.4.1.1) and branching enzyme (EC: 
2.4.1.18). This system enables us to produce GDs with strictly controlled molecular size (Mw/Mn value less than 
1.1) and particle size ranging from 10 nm to 40 nm. Furthermore, we have developed non-reducing end specific 
glycosylation technology of GD by using glucan phosphorylase and its substrate analogs. Glucan phosphorylase 
from Aquifex aeolicus can use not only its original substrate, glucose 1-phosphate, but also other hexose 1-
phosphates as substrate and transfer these hexoses moieties (glucuronic acid, glucosamine, N-acetyl 
glucosamine, galactose and mannose) to the non-reducing end of glucan. Using this enzymatic reaction, we can 
produce GDs whose surface is modified with these hexose residues. GDs having glucuronic acid and/or 
glucosamine residues are especially useful since they can be covalently conjugated with functional substances 
such as sugar chains, peptides, nucleotides and others. It is possible to control the conjugate ratio of the 
functional substance on the surface of GD. Surface engineered GD is a novel and versatile platform for 
carbohydrate drugs and drug carriers, and its application will be described. 
